http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0623025-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b7c771a8e251feb5f009538b46515f8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 |
| filingDate | 1992-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5792178db8841359918d53e335d32840 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4ef7f9b3b83d7f032beedc03f486ce9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33dbfe0eca19ea1cb2935eca6597ff13 |
| publicationDate | 1994-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0623025-A1 |
| titleOfInvention | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| abstract | The invention relates to vaccines and a means of vaccinating a vertebrate to prevent or regulate pathologies induced by specific T cells, including autoimmune diseases, as well as unregulated T cell replication. The vaccine consists of a T-cell receptor (TCR) or a fragment of that corresponding to a TCR present on the surface of pathology-inducing lymphocytes. The vaccine fragment can be a peptide corresponding to TCR sequences characteristic of the T lymphocytes inducing said pathology. Said peptide can bind to conventional antigens whose transformation into a complex makes it possible to obtain cells having antigens of major histocompatibility complex or superantigens. The invention also relates to means for determining suitable amino acid sequences for these vaccines. The vaccine is administered to vertebrates in a manner that induces an immune response to the pathology-inducing T-cell TCR. This immune response reduces or suppresses pathogenic T cells, thereby stopping the pathogenesis of the disease. The invention also relates to variable regions with specific beta chains of T cell receptors, called Vbeta3, Vbeta4, Vbeta12, Vbeta14 and Vbeta17, which are associated with the pathogenesis of autoimmune diseases, such as rheumatoid arthritis and sclerosis. plates. Furthermore, the invention relates to methods of administering DNA or RNA encoding the polypeptides useful as vaccines of the invention, in the tissue cells of an individual. |
| priorityDate | 1991-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 125.